Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.5%

1 terminated/withdrawn out of 202 trials

Success Rate

96.9%

+10.3% vs industry average

Late-Stage Pipeline

13%

26 trials in Phase 3/4

Results Transparency

0%

0 of 31 completed trials have results

Key Signals

83 recruiting

Enrollment Performance

Analytics

N/A
51(34.5%)
Phase 2
51(34.5%)
Phase 1
17(11.5%)
Phase 3
15(10.1%)
Phase 4
11(7.4%)
Early Phase 1
3(2.0%)
148Total
N/A(51)
Phase 2(51)
Phase 1(17)
Phase 3(15)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (202)

Showing 20 of 202 trials
NCT07458906Not ApplicableRecruiting

DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

Role: lead

NCT07452406Not ApplicableNot Yet Recruiting

Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients

Role: collaborator

NCT07383909Not ApplicableRecruiting

Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery

Role: collaborator

NCT03799653Recruiting

A Prospective Nurse Cohort Study in Xiamen, China

Role: lead

NCT07677774Not ApplicableRecruiting

GPC3-Targeted PET/CT in Hepatocellular Carcinoma

Role: lead

NCT07137052Recruiting

Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma

Role: lead

NCT07788001Phase 3Not Yet Recruiting

A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer

Role: collaborator

NCT07783100Phase 2Recruiting

Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT07778212Not ApplicableRecruiting

Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL

Role: lead

NCT07753499Not ApplicableRecruiting

Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer

Role: lead

NCT07749365Phase 2Recruiting

Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

Role: lead

NCT07692555Not Yet Recruiting

Development and Validation of a Colorectal Cancer Diagnostic Model

Role: collaborator

NCT07159035Not ApplicableCompleted

Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones

Role: collaborator

NCT07686796Phase 3Not Yet Recruiting

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Role: collaborator

NCT07677787Not ApplicableRecruiting

DLL3-Targeted PET/CT in Small Cell Lung Cancer

Role: lead

NCT07133620Not ApplicableRecruiting

the Effect of Transcutaneous Electrical Acupoint Stimulation on Postoperative Gastrointestinal Dysfunction After Urological Laparoscopic Surgery

Role: lead

NCT07623382Early Phase 1Recruiting

Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease

Role: lead

NCT07622693Active Not Recruiting

Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer

Role: collaborator

NCT07617675Phase 4Not Yet Recruiting

rhBNP for Prevention of Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)

Role: collaborator

NCT06465017Not ApplicableTerminated

ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer

Role: lead